Surpassing the emerging immune-checkpoint inhibitor market

Date

2016-01

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

84
views
46
downloads

Citation Stats

Abstract

Department

Description

Provenance

Subjects

Citation

Published Version (Please cite this version)

10.1158/2326-6074.CRICIMTEATIAACR15-A092

Publication Info

Vitek, Michael P (2016). Surpassing the emerging immune-checkpoint inhibitor market. CANCER IMMUNOLOGY RESEARCH, 4(1). 10.1158/2326-6074.CRICIMTEATIAACR15-A092 Retrieved from https://hdl.handle.net/10161/16044.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Vitek

Michael P. Vitek

Adjunct Associate Professor in Neurology

The overall interest of my laboratory is to identify the underlying causes of neurodegenerative diseases such as Alzheimer's disease. Once causes or experimental endpoints are determined, then strategies to find chemicals which can ameliorate pathophysiological events can be devised. In general, we are working to create transgenic animals and validate them as models of human disease.

Our specific approach has been to study the function of apolipoprotein-E (apoE) which Roses and colleagues found to a susceptibility factor for the presence of AD. Currently, our data are pointing to a relationship between apoE and oxidative stress where apoE appears to modulate nitric oxide production in a species specific manner. To further test this idea, we have created transgenic mice expressing the entire human NOS2 gene which will now be tested in various models of neurodegeneration and inflammation. Similarly, we are developing transgenic animals which express the human TAU gene. When properly stressed, these TAU-transgenic animals may display the neurofibrillary tangle pathology which is associated with neurodegeneration in a wide variety of neurological diseases.

If our transgenic animals prove to be validated models of human
disease, then the process to screen for chemicals which might alter the disease outcome in those models can begin in earnest. Should compounds be identified, then the various phases of clinical trials may proceed.

At present, my community service includes participation on the Alzheimer's Association Medical and Scientific Advisory Board and on the Neurological Sciences III Study Section for the National Institutes of Health extramural research program. I have previously served in a similar capacity for the American Health Assistance Foundation and the Long Island Alzheimer's Foundation. I have also had the pleasure to serve as a scientific consultant for various biotechnology companies.

Keywords: Neurodegeneration, Alzheimer's, Transgenic, Animal Models, Amyloid, Apolipoprotein-E, Molecular Biology, Biochemistry


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.